ABSTRACT HOGG, ROBERT W. (University of Illinois, Urbana), CHITRA S. BISWAS, AND HARRY P. BROQUIST. Interference with valine and isoleucine biosynthesis by cyclic hydroxamic acids. J. Bacteriol. 90:1265-1270. 1965.-The introduction of a hydroxyl group in a number of common barbiturates, a substitution which converts these compouinds to cyclic hydroxamic acids, gives rise to compounds which inhibit growth of Escherichia coli. The toxicity of these hydroxybarbiturates appears to be associated, at least in part, with interference with valine and isoleucine biosynthesis, as a combination of these amino acids counteracts their toxicity. A subinhibitory level of 1-hydroxy-5-ethyl-5-isopropylbarbituric acid (hydroxyipral) was counteracted either by valine or by its early precursor, a-acetolactate, and led to a study of the effect of these cyclic hydroxamic acids on acetolactate synthesis in a cell-free enzyme system of E. coli. In this system, the parent barbiturates and their respective hydroxy derivatives were only moderately active in blocking acetolactate synthesis. Detailed kinetic studies of the most active compound, hydroxyipral showed no obvious relationship to the substrate or cofactors of the system. The inhibitory effects of hydroxyipral, either on growth of E. coli or in the acetolactate-forming system, could not be counteracted by Fe++, but the toxic effect of aspergillic acid and o-phenanthroline in these instanices was reversed by Fe++, which implies an iron involvement in the acetolactate-forming system of E. coli.
Aspergillic acid, an antibiotic produced by Aspergillus flavus (White and Hill, 1943) , has been shown to be a pyrazine cyclic hydroxamic acid (Dutcher and Wintersteiner, 1944) (Fig. 1) . Its alkyl substituents suggest a relationship to the branched-chain amino acids and, indeed, it has been demonstrated (MacDonald, 1961) that isoleucine and leucine are precursors of aspergillic acid. Although this antibiotic possesses a potentially useful antibacterial spectrum, it is quite toxic (White and Hill, 1943) and hence of little interest clinically.
Some years ago Safir, Hlavka, and Williams (1953) sought to prepare compounds in the barbituric acid series, analogous in structure to aspergillic acid. By condensing appropriately substituted malonyl chlorides with benzyloxy urea and subsequently removing the benzyl group by hydrogenolysis, barbituric acids were obtained with the added feature of a hydroxyl group attached to a nitrogen atom, e.g., as in structure B, Fig. 1 . This substitution confers on the molecule the )roperties of a cyclic hydroxamic acid. Such compounds were found, however, to have only a low order of pharmacological activity (Safir et al., 1953) . It was subsequently discovered that these cyclic hydroxamic acids, like aspergillic acid, were antibacterial agents and that they appeared to interfere with the synthesis of valine and isoleucine in Escherichia coli (Biswas and Broquist, Bacteriol. Proc., p. 93, 1964) . The details of these findings are the subject of this communication.
MATERIALS AND METHODS
Source of compounds. Aspergillic acid was kindly provided by J. R. Dutcher, Squibb Institute for Medical Research, New Brunswick, N.J. The N'-hydroxybarbituric acid derivatives listed in Table 1 were kindly given to us by S. R. Safir, Lederle Laboratories Division, American Cyanamid Co., Pearl River, N.Y. Subsequently, additional 1-hydroxy-5-ethyl-5-isopropylbarbituric acid was required, which was prepared as described by Safir et al. (1953) . DL-a-Acetolactate was synthesized by the procedure of Krampitz (1948 Lowry et al. (1951) .
The complete reaction mixture contained the following: 10 umoles of Mg+, 100 ,ug of thiamine pyrophosphate (TPP), 5 ug of FAD, 100 jimoles of phosphate buffer (pH 8), test compounds, 0.2 ml of enzyme containing 0.5 mg protein, 20j,moles of pyruvate, and water to 1.9 ml. In actual practice, the complete system less pyruvate was allowed to come to 37 C before addition of substrate to initiate the reaction. The reaction was allowed to proceed for 15 min, and then was terminated by the addition of 0.1 ml of 36 N H2SO4 and heated at 60 C for 15 min. The precipitated protein was removed by centrifugation, the supernatant liquid was neutralized with sodium bicarbonate, and a 0.5-ml sample was removed for acetoin determination by the method of Westerfeld (1945) . Table 1 indicates that barbituric acid and several 5, 5-dialkyl derivatives commonly used pharmacologically are very weak inhibitors of growth of E. coli. However, the introduction of the hydroxyl group to the number 1 nitrogen atom of certain ot these barbiturates results in a marked enhancement of antibacterial activity. Nonetheless, the naturally occurring cyclic hydroxamic acid, aspergillic acid, was still one order of magnitude more potent in antibacterial activity. The feeble antibacterial activity of hydroxyphenobarbital may reflect the inability of this derivative, with its phenyl substituent, to enter the cell.
RESULTS
Attempts were made to reverse hydroxybarbiturate toxicity by natural materials and by use of selected metabolites. Such experiments led to the discovery that acid casein hydrolysate (1 mg/ml) counteracted the toxicity of these compounds, and that the effect of casein hydrolysate could be attributed to its combined content of valine and isoleucine. The effects of these branched-chain amino acids on hydroxybarbiturate inhibition in E. coli are illustrated in Table 2 . Valine plus isoleucine did not alter the toxicity of aspergillic acid for growth of E. coli.
In other experiments not shown in Table 2 , valine alone was more effective than isoleucine in reversing low levels of hydroxybarbiturate inhibition, but at higher levels a combination of both amino acids was always required for optimal growth. In the experiment in (Umbarger and Brown, 1958; Leavitt and Umbarger, 1961) . If the hydroxybarbiturates interrupt E. coli metabolism at this point, it becomes apparent why their toxicity is over- come by the combination of valine and isoleucine ( Table 2) .
The synthesis of acetolactate from pyruvate in a suitable cell-free enzyme system from E. coli was studied. Both the parent barbiturates and the hydroxybarbiturates under investigation showed significant inhibition of the system, although relatively high levels of these compounds were required (Table 4) . For example, 10 ,umoles of the barbiturates or their respective hydroxybarbiturates gave from 20 to 30% inhibition of acetolactate synthesis under the conditions of the experiment. Hydroxyipral, which was far more potent as a growth inhibitor than its parent barbiturate, ipral (Table 1) , was only about twice as active as ipral in blocking acetolactate formation (Table 4) . Aspergillic acid was the most potent cyclic hydroxymate in inhibiting the system, which was of particular interest since the antibacterial effect of this antibiotic is not reversed by isoleucine plus valine ( Table 2) . The possibility was considered that the effects of these cyclic hydroxamic acids on growth (Table 1 ) and on the acetolactate-forming system (Table 4) might be due at least in part to the binding of an essential cation such as Fe++(4+). Indeed, o-phenanthroline effectively inhibited acetolactate formation (Table 4) . This observation led to the experiments in Tables  5 and 6. A detailed kinetic study of the relationship between hydroxyipral and the substrate and cofactors of the acetolactate-forming system was performed to gain some insight into the mechanism of inhibition of this system by hydroxybarbiturate. The results expressed as double reciprocal plots are summarized in Fig.  2 . In confirmation of the findings of Umbarger and Brown (1958) , valine effectively inhibited the acetolactate-forming system in E. coli and was reversed competitively by the substrate, pyruvate. The relationship between hydroxyipral and pyruvate was not as clear-cut, however, and the kinetics appeared to be mixed in nature. When the substrate was kept constant and the cofactors FAD and TPP were varied, the kinetics of hydroxyipral inhibition were essentially noncompetitive (Fig. 2) . Table 5 indicates that the toxicity of hydroxyphenobarbital, aspergillic acid, and o-phenanthroline for growth of E. coli is reversed by Fe+ but not by Mg++; however, Fe+ did not alter the toxicity of hydroxyipral. In the acetolactateforming system (Table 6 ), Fe+ actually enhanced hydroxyipral inhibition, but the inhibitory action of aspergillic acid, o-phenanthroline, and, to a lesser extent, of a , a-dipyridyl was overcome by Fe+. mechanism other than interference with any cationic requirement in the enzyme system.
The possibility was considered, in view of certain structural features shared by hydroxyipral and valine (Fig. 1) , that hydroxyipral might coli (Table 1) . The possibility that hydroxyipral might be a repressor of synthesis of acetohydroxy acid synthetase is presently being considered.
Despite certain gross structural similarities between valine and hydroxyipral ( Fig. 1) , the latter should not be viewed as an antimetabolite of valine, for it is not a competitive antagonist of valine in growth experiments (Table 3) , and kinetic studies of its inhibitory action on acetolactate synthesis revealed significant differences when compared with valine (Fig. 2) .
The possibility that hydroxyipral, a cyclic hydroxamic acid, might be exerting its effect by complexing with an essential cation, particularly Fe+, was not borne out by experiment, but led to the finding that certain iron chelators, e.g., o-phenanthroline and a,a-dipyridyl, together with aspergillic acid, blocked acetolactate formation and that such inhibition was reversed by Fe-. If aspergillic acid interferes in general with iron metabolism in cells, it becomes understandable why valine and isoleucine alone failed to significantly alter the toxicity of this antibiotic for E. coli (Table 2 ). The finding that there is an iron requirement in the acetolactateforming enzyme system of E. coli takes on added significance in light of the recent recognition of the involvement of FAD in this enzyme system (St0rmer and Umbarger, 1964) . ACKNOWLEDGMENT This investigation was supported by grant GB 225 from the National Science Foundation.
